Table 2 Overview of pathogen reduction/inactivation technologies compatible with platelet concentrates
From: Bacterial contamination of platelets for transfusion: strategies for prevention
INTERCEPT™ Blood System for Platelets | Mirasol® Pathogen Reduction Technology System | THERAFLEX® UV-Platelets | |
|---|---|---|---|
Manufacturer | Cerus Corporation | Terumo BCT | MacoPharma |
FDA approval for platelets | Yes | No | No |
CE mark approval | CE class III | CE class IIB | CE class IIB |
Principle of method | UVA illumination in the presence of a photosensitizer | Broad-spectrum UV illumination in the presence of a photosensitizer | UVC illumination and intense platelet bag agitation |
Photosensitizer | Amotosalen | Riboflavin | None |
UV wavelength and dose | UVA, 320–400 nm, 3 J/cm2 | UVB/UVA/UVC (100%/60%/20%), 265–370 nm, 6.2 J/mL | UVC, 254 nm, 0.2–0.3 J/cm2 |
Pathogens targeted | Bacteria (Gram-positive and Gram-negative), viruses (enveloped and non-enveloped), parasites | Bacteria (Gram-positive and Gram-negative), viruses (enveloped and non-enveloped), parasites | Bacteria (Gram-positive and Gram-negative), viruses (enveloped and non-enveloped), parasites |
Toxicology testinga | Acute toxicology, carcinogenicity, general pharmacology, genotoxicity, phototoxicity, repeated dose, reproductive toxicology (plus others) | Acute toxicology, genotoxicity, phototoxicity, repeated dose, reproductive toxicology (plus others) | Not applicable (no exogenous photosensitizer) |
Bacterial inactivation (log reduction)b | |||
Gram-positive | 3.6 to >6.9 | 1.9 to 4.8 | 4.3 to >4.9 |
Gram-negative | 4.5 to >6.7 | 2.8 to 5.4 | >4.0 to >4.9 |
Maximum approved storagec | 5 and 7 days | 7 days | 5 days |